View the Latest INTERCEPT-related Coronavirus News Here.

COVID News

This page includes COVID-19 related press releases and information where Cerus, INTERCEPT or pathogen reduction is mentioned.

Recent Press Releases (COVID)

July 07, 2020
Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma
View Release

April 17, 2020
DARPA-funded microchip technology optimizes convalescent plasma therapy for COVID-19 patients
View Release

April 06, 2020
Cerus Corporation Provides Update on COVID-19 Related Activities
View Release

April 02, 2020
University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma
View Release

Recent News (COVID)

March 26, 2020

Cerus Forms Group to Research Optimal Production of COVID-19 Convalescent Plasma. 
Cerus Corporation has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, including the level and nature of anti-COVID-19 antibodies, optimal collection timing, dosing and how these influence responses to the therapy regimen. Cerus’ research group collaborators include the California Department of Public Health, the University of California, Irvine’s Vaccine Development Research Laboratory, the Vitalant Research Institute, the California National Primate Research Center, and Enable Biosciences.
Read the press release

May 29, 2020

Everything Old is New Again: Powerful Not-So-New Tool for the Battle Against COVID-19
Innovation HUB (WGBH-Boston)
Read the article

Safety and Sustainability

We are focused on ensuring the safety of our team and our stakeholders as we endeavor to achieve our mission of establishing INTERCEPT as the global standard of care. 

In the face of the current COVID-19 pandemic, we have implemented actions to:

  • Ensure the safety of our employees and their families
  • Sustain continuity of our supply chain to support current and anticipated demand for our products
  • Engage with regulatory authorities, blood centers, and national transfusion services to expand availability of the platelet supply
  • Study the efficacy of INTERCEPT against SARS-CoV-2
  • Support blood centers evaluating the use of Convalescent Plasma